Understanding the molecular basis of HBV drug resistance by molecular modeling

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 339-353

  Sharon, Ashoke ^a   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Drug resistance; Hepatitis B virus; Nucleoside analog; Polymerase inhibitor

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; ENZYME ACTIVE SITE; HEPATITIS B VIRUS; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

HEPATITIS B VIRUS;

EID: 56349134321     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.07.010     Document Type: Article

References (55)

1. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., and Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677
2. Angus P., and Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!. Antivir. Ther. 9 (2004) 145-148
3. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., and Ayres A. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
4. Ayres A., Locarnini S., and Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol. Med. 95 (2004) 125-149
5. Balakrishna Pai S., Liu S.H., Zhu Y.L., Chu C.K., and Cheng Y.C. Inhibition of hepatitis B virus by a novel l-nucleoside, 2′-fluoro-5-methyl-beta-l-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40 (1996) 380-386
6. Bartholomeusz A., Schinazi R.F., and Locarnini S.A. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepatitis Rev. 4 (1998) 167-187
7. Bartholomeusz A., Tehan B.G., and Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 9 (2004) 149-160
8. Bottecchia M., Ikuta N., Niel C., Araujo N.M., O K.M., and Gomes S.A. Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case. J. Gastroenterol. Hepatol. 23 (2008) 67-72
9. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., Trepo C., and Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (Baltimore) 41 (2005) 1391-1398
10. Bryant M.L., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., Dukhan D., Gosselin G., Imbach J.L., and Hernandez B. Antiviral l-nucleosides specific for Hepatitis B virus infection. Antimicrob. Agents Chemother. 45 (2001) 229-235
11. Chin R., Shaw T., Torresi J., Sozzi V., Trautwein C., Bock T., Manns M., Isom H., Furman P., and Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45 (2001) 2495-2501
12. Chong Y., and Chu C.K. Understanding the unique mechanism of l-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg. Med. Chem. Lett. 12 (2002) 3459-3462
13. Chong Y., and Chu C.K. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV. Antivir. Res. 63 (2004) 7-13
14. Chu C.K., Ma T., Shanmuganathan K., Wang C., Xiang Y., Pai S.B., Yao G.Q., Sommadossi J.P., and Cheng Y.C. Use of 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39 (1995) 979-981
15. Das K., Xiong X., Yang H., Westland C.E., Gibbs C.S., Sarafianos S.G., and Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75 (2001) 4771-4779
16. de Man R.A., Wolters L.M., Nevens F., Chua D., Sherman M., Lai C.L., Gadano A., Lee Y., Mazzotta F., Thomas N., and DeHertogh D. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34 (2001) 578-582
17. Delaney W.E., Edwards R., Colledge D., Shaw T., Torresi J., Miller T.G., Isom H.C., Bock C.T., Manns M.P., and Trautwein C. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of Hepatitis B virus. Antimicrob. Agents Chemother. 45 (2001) 1705-1713
18. Delaney W.E., Locarnini S., and Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir. Chem. Chemother. 12 (2001) 1-35
19. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., and Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333 (1995) 1657-1661
20. Dienstag J.L., Wei L.J., Xu D., and Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin. Drug. Investig. 27 (2007) 35-49
21. Ferir G., Kaptein S., Neyts J., and De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev. Med. Virol. 18 (2008) 19-34
22. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., and Banks J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47 (2004) 1750-1759
23. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
24. Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.W., Yueng Y.H., Wong A., Rousseau F., Yuen K.Y., Naoumov N.N., and Lau G.K. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J. Hepatol. 48 (2008) 714-720
25. Jacquard A.C., Brunelle M.N., Pichoud C., Durantel D., Carrouee-Durantel S., Trepo C., and Zoulim F. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob. Agents Chemother. 50 (2006) 955-961
26. Krishnan P., Gullen E.A., Lam W., Dutschman G.E., Grill S.P., and Cheng Y.-c. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of l-nucleoside analogs, a new class of anticancer and antiviral agents. J. Biol. Chem. 278 (2003) 36726-36732
27. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., and Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36 (2003) 687-696
28. Lai C.L., Lim S.G., Brown N.A., Zhou X.J., Lloyd D.M., Lee Y.M., Yuen M.F., Chao G.C., and Myers M.W. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40 (2004) 719-726
29. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
30. Langley D.R., Walsh A.W., Baldick C.J., Eggers B.J., Rose R.E., Levine S.M., Kapur A.J., Colonno R.J., and Tenney D.J. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81 (2007) 3992-4001
31. Lee H.S., Chung Y.H., Lee K., Byun K.S., Paik S.W., Han J.Y., Yoo K., Yoo H.W., Lee J.H., and Yoo B.C. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 43 (2006) 982-988
32. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., and Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6 (1999) 937-943
33. Leung N. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
34. Levine S., Hernandez D., Yamanaka G., Zhang S., Rose R., Weinheimer S., and Colonno R.J. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46 (2002) 2525-2532
35. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J. Hepatol. 39 Suppl. 1 (2003) S124-S132
36. Locarnini S., and Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44 (2006) 422-431
37. Locarnini S., Qi X., Arterburn S., Snow A., Brosgart C.L., Currie G., Wulfsohn M., Miller M., and Xiong S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. 42 (2005) 17
38. Marcellin P., Mommeja-Marin H., Sacks S.L., Lau G.K., Sereni D., Bronowicki J.P., Conway B., Trepo C., Blum M.R., Yoo B.C., Mondou E., Sorbel J., Snow A., Rousseau F., and Lee H.S. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
39. McGovern B. Antiretroviral therapy for patients with HIV-hepatitis B virus coinfection. Clin. Infect. Dis. 44 (2007) 1012-1013
40. Ono-Nita S.K., Kato N., Shiratori Y., Carrilho F.J., and Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob. Agents Chemother. 46 (2002) 2602-2605
41. Palumbo E. New drugs for chronic hepatitis B: a review. Am. J. Ther. 15 (2008) 167-172
42. Poch O., Sauvaget I., Delarue M., and Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8 (1989) 3867-3874
43. Sasadeusz J.J., Locarnini S.L., and Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B?. Med. J. Aust. 186 (2007) 204-206
44. Seeger C., and Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64 (2000) 51-68
45. Sherman W., Day T., Jacobson M.P., Friesner R.A., and Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
46. Steitz T.A. A mechanism for all polymerases. Nature 391 (1998) 231-232
47. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., and Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33 (2001) 751-757
48. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., and Colonno R.J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48 (2004) 3498-3507
49. Tirado-Rives J., and Jorgensen W.L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 49 (2006) 5880-5884
50. Wilchek M., Bayer E.A., and Livnah O. Essentials of biorecognition: the (strept)avidin-biotin system as a model for protein-protein and protein-ligand interaction. Immunol. Lett. 103 (2006) 27-32
51. Williams D.H., Stephens E., O'Brien D.P., and Zhou M. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. Angew. Chem. Int. Ed. Engl. 43 (2004) 6596-6616
52. Yadav V., and Chu C.K. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study. Bioorg. Med. Chem. Lett. 14 (2004) 4313-4317
53. Yoo B.C., Kim J.H., Chung Y.H., Lee K.S., Paik S.W., Ryu S.H., Han B.H., Han J.Y., Byun K.S., Cho M., Lee H.J., Kim T.H., Cho S.H., Park J.W., Um S.H., Hwang S.G., Kim Y.S., Lee Y.J., Chon C.Y., Kim B.I., Lee Y.S., Yang J.M., Kim H.C., Hwang J.S., Choi S.K., Kweon Y.O., Jeong S.H., Lee M.S., Choi J.Y., Kim D.G., Kim Y.S., Lee H.Y., Yoo K., Yoo H.W., and Lee H.S. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45 (2007) 1172-1178
54. Yoo B.C., Kim J.H., Kim T.H., Koh K.C., Um S.H., Kim Y.S., Lee K.S., Han B.H., Chon C.Y., Han J.Y., Ryu S.H., Kim H.C., Byun K.S., Hwang S.G., Kim B.I., Cho M., Yoo K., Lee H.J., Hwang J.S., Kim Y.S., Lee Y.S., Choi S.K., Lee Y.J., Yang J.M., Park J.W., Lee M.S., Kim D.G., Chung Y.H., Cho S.H., Choi J.Y., Kweon Y.O., Lee H.Y., Jeong S.H., Yoo H.W., and Lee H.S. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 46 (2007) 1041-1048
55. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., Litwin S., Furman P.A., Jilbert A.R., and Mason W.S. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75 (2001) 311-322